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The Role of Inflammation in 
Amyloid Diseases
Estefania P. Azevedo and Debora Foguel
Abstract
Amyloid diseases are characterized by the abnormal accumulation of protein-
aceous aggregates (amyloid fibrils or plaques) in tissues and organs. This class of 
diseases is also characterized by the presence of inflammation. Amyloid fibrils arise 
from the partial denaturing and unfolding of native proteins. The accumulation 
of amyloid fibrils causes tissue damage and elicits local and nonlocal immune cell 
infiltration into tissue and proinflammatory cytokine production. Moreover, these 
conditions fuel a vicious cycle that can increase amyloid production and create 
an environment of chronic inflammation. A chronically inflamed tissue rapidly 
deteriorates and loses its function. In this chapter, we will discuss important data 
gathered over the years describing the role of inflammation in amyloid diseases. We 
will describe how inflammation begins and how it affects disease progression for 
major amyloid diseases, such as Alzheimer’s disease (AD) and hereditary TTR amy-
loidosis (hATTR). Lastly, we will discuss the recent advancements in treatments for 
amyloid diseases and how they address inflammation in affected patients.
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1. Introduction
In 1849, the term “amyloid” was first introduced by Matthias Schleiden to 
describe a starch-like material identified by an iodine-sulfuric acid staining of 
plant tissues [1]. Later in 1854, Rudolph Virchow observed similar deposits in 
human nervous tissue that reacted in an analogous manner as the deposits in 
plants after the addition of Schleiden’s iodine-sulfuric acid stain [1]. With the 
advance in technological power and the advent of microscopy, researchers found 
that the starch-like deposits found in the diseased tissues of humans were made of 
proteinaceous structures that were organized as fibrils (termed “amyloid fibrils”) 
and coated with carbohydrates, hence the reaction to iodine-sulfuric acid stains 
[1]. More than 40 pathologies are part of the family of diseases characterized as 
“Amyloid Diseases” [2]. The criteria that allow such characterization rely on the fact 
that these pathologies contain a very specific hallmark: the accumulation of amyloid 
fibrils in cells, tissues and/or organs. Fibrils are formed after native proteins partly 
unfold and aggregate into oligomers or amorphous aggregates that later organize 
themselves into mature, β-sheet-rich fibrillar structures [2]. On a molecular level, 
amyloid fibrils extracted from different patients can be indistinguishable from 
each other [2]. These structures can be formed outside the cell or inside the cell 
[2], and when they accumulate, they cause cellular damage or mechanical damage 
(if  accumulating in between or on top of tissues).
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For decades, scientists believed that amyloid fibrils were stable and inert, and 
the end result of a nontoxic natural pathway that serves to scavenge and store 
highly reactive and toxic oligomeric intermediates formed during the process of 
protein folding [3–5]. The reactive hydrophobic residues found exposed in oligo-
meric intermediates are hidden in mature amyloid fibrils, thus unable to react with 
important cellular components [6]. Although the latter is true about amyloid fibrils, 
research in the last two decades shows that these structures are neither inert nor 
nontoxic [5, 7]. When extracellular, amyloid fibrils are readily identified by the host 
immune system, mainly by macrophages or neutrophils [8–10]. These immune cells 
have receptors that recognize and bind to the amyloid fibrils and intermediates, 
activating a signaling cascade that results in the production of proinflammatory 
molecules [8–10]. In this chapter, we will review the inflammatory component 
of some clinically important amyloid diseases, such as Alzheimer’s disease (AD) 
and familial amyloid pathologies, such as hereditary TTR amyloidosis (hATTR or 
familial amyloid polyneuropathy—FAP). We will also discuss how inflammatory 
cells contribute to disease progression by causing bystander damage to tissues or 
by enhancing protein aggregation, in the case of AA amyloidosis. Finally, we will 
provide the recent therapeutic approaches based on immune regulatory strategies 
for these diseases.
2. Inflammation in amyloid diseases
Inflammation is the term given to a form of immune defense that is widespread 
and requires a complex network of immune effector mechanisms to address tissue 
dysfunction or injury. The notion that inflammation is involved in amyloid patho-
genesis was first suggested in the 1970s in two reports on serum amyloid A (SAA) 
[11, 12]. Nowadays, it is known that this particular amyloidogenic protein expres-
sion is regulated by IL-6, an inflammatory cytokine, which results in increased 
levels of SAA [13]. Hyperexpression of SAA for long periods of time results in 
amyloid formation and deposition in tissue, characterizing amyloid A (AA) amy-
loidosis [13]. This particular type of amyloidosis occurs in chronic inflammation 
conditions, such as autoimmune diseases or cancer [13]. With the exception of 
inflammation-induced amyloidosis, such as AA amyloidosis, the role of inflam-
mation in most amyloid diseases is a more recent concept that emerged in the late 
1980s with the observation of microglia, a brain immune cell, found near amyloid 
plaques in postmortem brain tissue from Alzheimer’s disease (AD) patients [14–16]. 
After these first observations, more evidence on the involvement of inflammatory 
mechanism in amyloid pathogenesis has emerged.
2.1 Alzheimer’s disease (AD)
Alzheimer’s disease (AD) is known as the most common neurodegenerative 
disease worldwide. It afflicts over 40 million people in the world, and because aging 
is the major risk factor for developing AD, its incidence will likely increase in the 
future as medical advances lead to increasing life span [17]. Although there is no 
definite known causative agent, most scientists agree that amyloid-β peptide (Aβ) 
is an important factor leading to AD [18]. Aβ is highly amyloidogenic, meaning 
that it has great potential to aggregate in solution [18]. Aβ is a small peptide ranging 
from 25 to 42 amino acids [18]. Extracellular aggregates of Aβ are the main protein 
present in amyloid plaques, a hallmark of AD [18]. Moreover, a small fraction of 
AD patients is diagnosed with familial AD, which is known to be the result of an 
infrequently inherited autosomal dominant mutation in one of the three genes 
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involved with the production of Aβ: the amyloid precursor protein (APP) gene, 
presenilin 1 (PSEN1), and presenilin 2 (PSEN2) [19]. The first findings pointing to 
a possible involvement of inflammatory mechanisms emerged around 1980 when 
scientists reported reactive microglia and astrocytes surrounding amyloid plaques 
of AD patients [14–16]. Nowadays, after years of research, inflammation is known 
to be implicated in AD by having a role in neuronal damage [20], Aβ generation 
[21], increased hyperphosphorylation of tau protein [22] (another hallmark of AD), 
and cognitive impairment [23]. In this part of the chapter, we will be focusing on 
summarizing the role of microglia in the progression of AD.
2.1.1 Role of microglia in AD
Microglia are the immune cells of the brain. They derive from myeloid precur-
sors which migrate into the brain during early embryonic development and play 
a major role in maintaining a healthy environment in the brain [24, 25]. Microglia 
use their surface receptors to constantly scan the central nervous system (CNS) for 
microbes or other damaging molecules [26]. When activated by a stimulus, microg-
lia mediate innate and adaptive immune responses or perform various functions 
in response to CNS disease or injury [26]. Microglia are of great importance for 
brain homeostasis, but uncontrolled or overactivated microglia can also contribute 
to brain diseases, such as AD.
Years of research is allowing deeper understanding of how microglia contribute 
to AD. Microglia produce inflammatory mediators, such as TNF-α [26], that can 
have a detrimental role when overproduced for long periods of time. Microglia are 
able to produce large quantities of TNF-α upon exposure to fibrillar and oligomeric 
Aβ [23, 27]. TNF-α is increased in the serum and CSF of AD patients and has 
additionally been detected in amyloid plaques [28–32]. Inhibiting TNF-α produc-
tion with the use of unspecific anti-inflammatory compounds, such as minocycline, 
or a specific neutralizing TNF-α antibody, (infliximab) results in downregulated 
inflammatory pathways (e.g., MAPK, AKT, and NF-κB) and abrogates cognitive 
deficits in mice [23, 33]. It has been shown that fibrillar and oligomeric Aβ can 
induce production of not only TNF-α but also other important inflammatory 
cytokines in microglia by binding and activating several receptors [23, 34]. This 
suggests the existence of a universal epitope found in aggregated material and a 
nonspecific response to amyloids. Also supporting this idea is the fact that two 
generic, widely used, conformation-specific antibodies have been generated (A11 
and OC antibodies) that recognize mutually exclusive structural epitopes in a range 
of amyloid-forming proteins, including Aβ, independently of any primary amino 
acid sequence similarities. A11 antibodies recognize anti-parallel β-sheet structures 
found in intermediate states, and OC antibodies detect parallel β-sheets found in 
mature amyloid fibrils [35]. Inflammation is a downstream consequence of aggre-
gated Aβ binding to receptors such as TLR-4 (toll-like receptor 4), RAGE (receptor 
for advanced glycation end products), CD36 [23, 36, 37], etc. It is important to note 
that some of these receptors are also able to recognize other aggregated non-Aβ 
materials [38]. Interestingly, these receptors are not only present in microglia, but 
some are also present in endothelial cells and neurons [39]. This suggests that the 
role of Aβ in AD is very complex.
Some receptors that primarily bind monomeric Aβ are not involved in patho-
logical, inflammatory processes. Receptors such as LRP1 (low-density lipoprotein 
receptor-related protein 1), PrPc (cellular prion protein), and PICALM (phosphati-
dylinositol-binding clathrin assembly protein) are able to bind monomeric Aβ and 
are thought to be involved in Aβ clearance, decreasing the Aβ burden and plaque 
formation in the brain [40]. Moreover, mutations in PICALM, which is a gene 
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that encodes a clathrin assembly protein and thus is involved in endocytosis, have 
been shown to be a risk factor for developing late-onset AD [41]. More convincing 
evidence of the significant role of neuroinflammation in AD is found in recent 
genome-wide association studies (GWAS). These studies have identified more 
than 20 gene variants as risk factors for developing late-onset AD. These disease-
modifying genes include genes involved in both innate and adaptive immune system 
responses: CR1, CLU, CD33, MS4A, ABCA7 EPHA1, TREM2, and HLA-DRB5/
HLA-DRB1 [41, 42]. It is interesting to note that all of these genes are present in 
microglia cells as well [41]. It is thought that these genes can change microglia func-
tion and increase the risk of AD.
2.1.2 Role of peripheral inflammation in AD
An emerging concept based on recent work is that peripheral inflammation, in 
addition to local, brain inflammation, also affects AD pathogenesis. Studies suggest 
that myeloid cells, such as neutrophils, can enter the brain and may also involve in 
Aβ clearance [10, 43]. Neutrophils can recognize fibrillar Aβ and produce in vitro 
and in vivo extracellular traps (NETs; a defense mechanism that results in neutro-
phil cell death) [10, 43]. Extracellular traps are protein and DNA-made meshes that 
can immobilize Aβ particles, degrade fibrillar amyloids, but are known to modulate 
other immune system effector mechanisms as well [44].
Acute systemic inflammation, caused by bacterial infection, exacerbates AD 
pathology [45], and chronic systemic inflammation, occurring in diseases such 
as rheumatoid arthritis (RA), depression, and obesity, has also been reported to 
modify the amyloid phenotype of AD mice and is considered common co-morbid 
states of AD patients. In autoimmune disease, chronic inflammation can increase 
the risk of developing AD. Patients with the autoimmune disease Sjögren’s syn-
drome (SS) are twice as likely to develop AD [46]. In RA, it has been shown that 
anti-TNF-α therapy has a protective effect on dementia [47]. In the case of depres-
sion, Aβ accumulation in AD mouse models induces depressive-like behavior, which 
is dependent on inflammation [23]. Inflammatory cytokine production reduces 
serotonin levels and contributes to behavioral changes in mice with AD [23]. Again, 
this can be prevented by anti-TNF-α therapy [23]. Obesity is a known comorbidity 
of AD and a low-grade chronic inflammatory disease. In humans and AD mouse 
models, cafeteria diet consumption and a higher BMI are known to accelerate AD 
pathology [48, 49]. For example, in humans, for every 1.0 increase in BMI at age 
70 years, AD risk increased by 36% in female patients [49].
In an attempt to cure AD, active immunization against Aβ was performed in 
mice and humans [50, 51]. Studies reported that immunization had a therapeutic 
effect on mouse models of AD [50–52]. Unfortunately, clinical Aβ vaccination trials 
have been interrupted due to the development of meningoencephalitis in 6% of 
the patients, likely involving the appearance of pro-inflammatory macrophages, 
CD4+ and CD8+ T cells [50]. As well as myeloid cells, T cells can enter the brain. 
There are myriads of T-cell subtypes surveilling the CSF and the meningeal mem-
branes [53], and they can enter the brain parenchyma upon cell injury [53]. It is 
not only brain-local T cells that react to Aβ but also blood T cells have been shown 
to have hyperreactivity to the Aβ peptide [54], specifically to epitopes within the 
residues 15–42 [54]. This evidence together suggests that the immune system and 
inflammation play significant roles in AD: not only helping with homeostatic Aβ 
clearance and preventing AD plaque formation but also by contributing to cell 
injury. Unfortunately, to date, tackling the immune system to prevent AD has yet to 
prove clinically effective.
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2.2 Hereditary ATTR (hATTR) amyloidosis
Transthyretin (TTR) is a 55-kDa tetrameric protein expressed and secreted 
mainly not only by the liver, but also by the choroid plexus in the brain [55]. This 
protein received this specific name due to its function: once in the plasma or 
in the cerebrospinal fluid, TTR acts as a retinol-binding protein and thyroxine 
transporter across the body [55]. More than 100 point mutations in the TTR gene 
have been described worldwide and most of them culminate in the production of 
abnormal protein with a high thermodynamic instability compared to its wild-type 
counterpart [55]. Only a handful of mutations are not pathogenic, such as the 
T119M mutation [56]. The pathogenic V30M variant is the most common mutation 
affecting a large population of people worldwide and results in the accumulation of 
TTR in various tissues, such as cardiac and nervous tissue [57]. Most TTR muta-
tions have a high propensity to aggregate under denaturing and even physiological 
conditions [58], forming amyloid fibrils that deposit in various tissues and organs 
[58]. For decades, most physicians and pathologists still regard hATTR amyloidosis 
as a disease without an inflammatory component, since most biopsies and ex vivo 
analysis showed no leukocyte infiltration [59]. However, with the appearance of 
new data in the last decade, hATTR amyloidosis is now being recognized as a dis-
ease with an important inflammatory component. Moreover, TTR amyloid fibrils 
are similar in structure to other amyloid fibrils and thus should induce similar 
inflammatory responses. One of the most common types of hATTR amyloidosis is 
known as familial amyloid polyneuropathy (FAP). FAP is an autosomal dominant 
hereditary disease characterized by the accumulation of amyloid fibrils in periph-
eral nerves, the gastrointestinal tract, and the heart [59]. This disease has three 
discernable stages: FAP 1 = unimpaired ambulation; mostly mild sensory, motor, 
and autonomic neuropathy in the lower limbs; FAP 2 = assistance with ambula-
tion required; mostly moderate impairment progression to the lower limbs, upper 
limbs, and trunk; FAP 3 = wheelchair-bound or bedridden; severe sensory, motor, 
and autonomic involvement of all limbs. This disease, as most amyloidosis, is 
incurable and results in death [59].
The diagnosis of FAP is challenging, often relying on genetic screening to identify 
TTR mutations as well as on the identification of Congo red-positive amyloid deposits 
in biopsies. These biopsies are generally invasive, and tissue is usually taken from 
the sural nerve, abdominal fat, or salivary glands [59]. The main go-to treatment for 
FAP is liver transplantation (LT), since the liver is the major organ of TTR produc-
tion. Unfortunately, LT presents mortality risks, and it is not available to all patients 
[60]. More recently, two new drug-based treatments have been FDA approved. One 
of these treatments use a new drug (Tafamidis) that works by stabilizing the TTR 
protein that is available in several countries showing effective results in controlling 
disease progression [61]. The other, just recently approved by the FDA, uses antisense 
oligonucleotides (ASOs) to target TTR production in the liver directly, decreasing the 
amount of TTR in the plasma, thus reducing protein aggregation [62].
Since the first study in 2001, the new concept that inflammation may play a role 
in the pathogenesis of FAP has emerged. Sousa and colleagues showed the presence 
of proinflammatory markers such as TNF-α and IL-1β in biopsies of FAP patients 
[63, 64]. Interestingly, the levels of proinflammatory and oxidative markers in 
ex vivo tissue positively correlate with the scoring stage proposed by Coutinho and 
colleagues in FAP patients, which is an index used to discriminate disease progres-
sion [65]. In addition, their study also showed the participation of the receptor 
RAGE, which can also bind Aβ fibrils, in the recognition of TTR amyloid fibrils 
[63]. In this first study, the authors suggest that Schwann cells, which are cells 
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that myelinate peripheral nerves, were responsible for the cytokine production 
observed in the neural tissue. A few years later, the presence of neutrophil-derived 
proteins in TTR amyloid deposits was described [66]. Proteins such as lipocalin and 
metalloproteinases were found together with TTR deposits in FAP patients [66]. 
The authors suggest that the sural nerve itself is the possible tissue producing these 
proteins for extracellular matrix remodeling and might be an effort to degrade amy-
loid fibrils deposited around them. Interestingly, a forgotten report in 1986 already 
reported the presence of neutrophil-derived proteins in amyloid-containing tissue 
[67]. The report in 1986 describes the presence of elastase, a neutrophil’s granule 
enzyme, in amyloid-containing tissue from patients diagnosed with AA amyloi-
dosis, primary amyloidosis caused by immunoglobulin light-chain aggregation 
and hATTR amyloidosis [67]. Notably, intact neutrophils were not found, which 
confirms the most pathologist reports of FAP tissues not having leukocyte infiltra-
tion. But how intracellular components from neutrophils appeared in amyloid-
containing tissue? Azevedo and colleagues reported in 2012 that a common epitope 
found in amyloid fibrils arising from different proteins, one of them being TTR, are 
able to activate neutrophils and induce elastase secretion in the form of extracellular 
traps [10]. These structures, called neutrophil extracellular traps (NETs), represent 
an important strategy to immobilize and kill invading microorganisms or in this 
case, aggregated proteins. The NET scaffold consists of DNA fibers associated with 
various granule proteins, one of them being elastase [10]. These elastase  
and DNA-traps accumulate in amyloid tissue and thus could explain why 
 elastase and neutrophil-derived proteins are found around amyloid tissues in FAP 
patients [10]. This immune response could also be an effort to eliminate amyloid 
fibrils or oligomers from the affected tissue. In 2012, another important report 
by Buxbaum and colleagues used an animal model of FAP to study the disease 
progression in mice [68]. The study showed the increased levels of inflammation-
related transcripts in both liver and heart of transgenic mice, strengthening the 
concept that inflammation might play an important role in FAP progression [68]. 
Additionally, Kurian and colleagues have observed sex-specific changes in blood 
cell gene expression in FAP patients, suggesting that inflammatory gene markers 
in circulating blood cells might be influenced by sexual dimorphisms [69]. More 
recently, new evidence shows the presence of elevated levels of IL-6 in FAP carriers 
that may be produced by myeloid cells and T cells [70].
These studies altogether suggest that inflammation in FAP consists of two differ-
ent phases. One phase in which inflammation possibly begins at the moment of TTR 
production in the liver. The synthesis and abnormal folding process of the mutated 
and unstable TTR in the liver requires a high energetic state and thus, may cause 
endoplasmic reticulum (ER) stress and the activation of the liver unfolding protein 
response (UPR). ER stress and the activation of UPR in liver were shown to cause 
pro-inflammatory cytokines production, such as IL-6 [71, 72]. IL-6 is known to 
increase the production of other proinflammatory intermediates and could enhance 
inflammation levels locally in the liver by activating liver-associated macrophages as 
seen in other nonamyloid diseases [73, 74]. It is ultimately important to understand 
whether the liver plays an important role in the inflammation observed in FAP 
patients due to the fact that most of these patients undergo domino liver trans-
plant. In this procedure, a liver failure patient receives a liver from a FAP patient. 
However, a five-year study described that 35% of patients that underwent domino 
liver transplantation presented FAP symptoms earlier than donor FAP patients 
[75]. These data indicate that FAP patients may have altered liver capacity and a 
low-grade chronic inflammation, decreasing the success of liver transplants. The 
second phase occurs after unstable TTR reaches the bloodstream and aggregation 
starts. TTR oligomers have been found in blood from FAP patients [76] and could 
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elicit the production of various inflammatory cascades in circulating leukocytes and 
T cells. Amyloid oligomers are formed before fibril deposition and have been shown 
to be toxic to cells [77] and elicit inflammation when presented to immune cells 
[23]. Small, toxic oligomers can also be produced in situ after the cleavage of mature 
fibrils through the action of local proteases, such as elastase and metalloprotein-
ase-9 [10, 66].
So far, in FAP patients and hATTR mouse models as well as in vitro, TTR fibrils 
are able to elicit inflammation and activate a myriad of cell types. In a broader clini-
cal context, the underlying inflammation that begins in asymptomatic patients and 
continues chronically might be important for the development of FAP-associated 
symptoms. Patients with FAP present symptoms other than neuropathy, such as 
gastrointestinal symptoms, cachexia, malnutrition, diarrhea, and others [59]. 
Inflammatory molecules are known to change neuroendocrine pathways leading 
to anorexia and thus cachexia in FAP patients. These new data point to an expla-
nation for a lot of unknowns concerning the pathogenesis of FAP. Additionally, 
understanding the role of inflammation in hATTR will help improve the quality of 
life and disease management in affected patients. There are currently no studies 
showing if inflammation can increase the risk of developing hATTR. However, it 
is possible that an inflammatory environment could decrease liver function and 
predispose an individual for the production of misfolded proteins, such as TTR.
2.3 Other amyloid diseases
Although recent papers have confirmed that amyloid fibrils present polymor-
phisms in topology, amyloids still possess an unchangeable structural fingerprint 
that is shared across species [78]. A lot of different proteins are able to form amyloid 
fibrils and not all amyloids are pathogenic. Various hormones are present in amy-
loid form in the pituitary gland [79], and melanocytes possess amyloids, which 
contribute to melanin formation [80], etc. What makes an amyloid pathogenic or 
not is still unclear. However, amyloids also possess another universal characteristic: 
they are able to activate the immune system and induce inflammation. This sug-
gests that inflammation may be an important component of many other amyloid 
diseases. Indeed, inflammation has been described in many other amyloid diseases. 
In Parkinson’s disease (PD), the involvement of inflammation in the disease process 
is supported by data showing the infiltration of activated microglia and T cells in 
post-mortem PD brains [81, 82] Additionally, there is accumulation of proinflam-
matory cytokines such as TNF-α, IFN-γ, and IL-6 IL-1β in the brain and cerebrospi-
nal fluid of PD patients [83, 84]. The PD culprit protein, α-synuclein, is able to bind 
to several immune receptors and elicits in vitro and in vivo inflammatory response 
[85]. Local inflammation has been thoroughly reported for PD patients, mainly 
derived from activated microglia [82, 85]. Protein aggregation in PD extends well 
beyond the CNS and also affects peripheral autonomic neuronal circuits, such as the 
enteric nervous system [86]. Gut inflammation has been recently reported in PD 
and is thought to be an important component of the disease [86].
Prion disease is another widely studied amyloid disease and is also known as 
Creutzfeldt-Jakob disease, fatal insomnia, spongiform encephalopathy, and Kuru. 
Prion diseases are rare, progressive neurodegenerative disorders that affect both 
humans and animals [87]. They are caused by the aggregation of PrPc (cellular 
prion protein) into transmissible, pathogenic prions [87]. These diseases are accom-
panied by long incubation periods and brain changes associated with neuronal loss 
[87]. Identifying a role of inflammation in these diseases is rather recent and begun 
with studies showing that the pathological hallmarks of the prion diseases are asso-
ciated with the presence of activated astrocytes and microglia [88]. CD8+ T cells are 
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also present in prion-affected brains and usually are found near activated microglia 
and prion amyloid plaques [89]. As inflammation progresses, inflammatory cyto-
kines are also detected in prion-containing brains [88], and these are thought to 
play an important role in behavioral changes and neuronal loss observed in affected 
mice. And this is yet another example of inflammation being widely present and 
contributing to pathogenesis in an amyloid disease which was first thought to not 
have an inflammatory component.
3. What is in store for the future: Therapies for amyloid diseases
Most amyloid diseases are still incurable. However, most of them can be 
managed using palliative care and drugs to decrease symptoms and extend 
the patients’ lives. In AD, efforts are concentrated in decreasing symptoms 
such as cognitive deficits [90]. Currently, there are five FDA-approved drugs 
to treat cognitive symptoms associated with AD. These drugs are basically 
acting on two different neurotransmitter systems in the brain: the cholinergic 
system and the glutamatergic system [90]. They act by blocking glutamate 
receptors and inhibiting cholinesterase activity, thus these drugs, when 
combined, can decrease excitotoxicity induced by an overload of glutamate in 
the synapse and making acetylcholine more available for a healthy synaptic 
transmission [90]. While in theory, and as seen in mouse models of AD, these 
drugs seem effective, in humans they work to certain extent decreasing the 
symptoms. Although these drugs can temporarily decrease symptoms, they 
are not able to stop the progression of AD, as they do not address amyloid 
accumulation [90]. Although great results were seen in mouse models, in AD 
patients, clinical trial using nonsteroidal anti-inflammatory drugs (NSAID) 
were unsuccessful to prevent or treat the disease, but these drugs only 
account for a small part of inflammatory pathways dependent on cyclooxy-
genases (COX) and have diverse side effects. For PD, treatment using drugs 
is aimed at enhancing cholinergic and dopaminergic transmissions and hence 
decreasing motor and gut-related symptoms, such as tremors and constipa-
tion [91]. Deep-brain stimulation is a surgical treatment available for PD 
and can also decrease motor symptoms [91]. Most treatments, as the ones 
described above, are aimed at treating the consequence of amyloid accumula-
tion rather than treating the amyloid accumulation itself or the inflammatory 
components of these many amyloid diseases.
For the hATTR diseases, two FDA-approved drugs have been developed to 
prevent amyloid accumulation in patients: tafamidis, a drug that stabilizes TTR 
and decreases TTR aggregation and antisense oligonucleotides against TTR, a drug 
that aims in reducing TTR production in the liver [61, 62]. In structure, tafamidis 
resembles most NSAID, and hence, it does not have any NSAID activity [92]. 
Notably, many other NSAID drugs also bind to TTR, stabilizing it [93]. However, 
many have not been to clinical trials at all or have not been successful in clinical 
trials because chronic use of NSAIDs is not indicated for patients with liver, renal, 
and heart problems [94], which are part of the symptoms affecting FAP patients. 
NSAIDs have also been used for treating other amyloid diseases, such as AD and 
PD, but again without success [95, 96]. Indeed, many AD and PD patients are older 
individuals that also possess additional conditions that exclude them from the 
chronic use of NSAIDs. The use of immunotherapies, especially for AD, has been 
thought to be an effective approach to treating the disease, but clinical trials have 
shown that autoimmune meningoencephalitis develops in a significant number 
of patients undergoing immunotherapy [50]. Usually these treatments aim to use 
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antibodies to neutralize the culprit of the disease, in the case of AD, the Aβ peptide 
[50]. Unfortunately, the autoimmune response, consisting of hyperreactive T cells, 
of patients has prevented the clinical trials from continuing further. Researchers are 
still investigating immunotherapies as a way to treat AD and managing the T cell 
response.
The use of antisense nucleotides (ASOs) for successfully decreasing the amount 
of native protein in the body remains the most effective therapy and maybe the path 
to cure amyloid diseases. ASOs have already been shown to be effective in hATTR 
disease [62], without eliciting any further autoimmune inflammatory response in 
patients receiving the therapy. There is growing interest in using ASOs in AD and 
PD, since many proteins that cause amyloid diseases have unknown or redundant 
physiological function [2]. This suggests that decreasing the levels of native, healthy 
protein in individuals may not cause problems for most bodily functions. By reduc-
ing the levels of native protein, ASOs ultimately decrease amyloid formation and 
accumulation and finally, all the immune responses that might come with unstable 
protein synthesis, aggregation, and amyloid deposition in tissue.
4. Conclusion
Amyloid diseases have been described in humans and animals since the 
1800s. This family of diseases has one defining characteristic: the presence of 
extracellular proteinaceous aggregates (amyloid fibrils or plaques) in tissues and 
organs. These amyloid fibrils arise from the unfolding of native protein, which 
vary according to the disease (for example, Aβ peptide in AD). Another common 
characteristic of amyloid diseases is the installment of inflammation during and 
after amyloid formation. Amyloid fibrils and tissue damage elicit local and nonlo-
cal immune cell infiltration into tissue and proinflammatory cytokine production. 
Together, these fuel a vicious cycle that can increase amyloid production, as 
seen in AA amyloidosis, and create an environment of chronic inflammation. A 
chronically inflamed tissue, as seen in autoimmune diseases, rapidly loose func-
tion and deteriorates. This is especially true for the nervous system, a delicate 
tissue in which self-repair is almost impossible. As most amyloid diseases affect 
the CNS, and inflammation is a fundamental component of amyloid disease, 
 studying inflammation in the CNS is imperative to our understanding of how 
to treat amyloid disease. Many current treatments focus on the consequences of 
amyloid accumulation and fail to address the basic underlying causes. The use 
of ASOs brings promise of improvements in amyloid disease therapeutics and 
fortunately is growing as an important tool used in disease therapy. Recognizing 
that inflammation plays a significant role in amyloid disease is essential to under-
stand the pathogenesis of amyloidosis and important for developing new targeted 
treatments in an era of growing demand.
Acknowledgements
I would like to thank Dr. Kristina Hedbacker for careful proof reading of this 
chapter.
Conflict of interest
We report no conflict of interest.
Amyloid Diseases
10
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Estefania P. Azevedo1* and Debora Foguel2
1 Laboratory of Molecular Genetics, The Rockefeller University, New York, NY, USA
2 Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
*Address all correspondence to: eazevedo@rockefeller.edu
11
The Role of Inflammation in Amyloid Diseases
DOI: http://dx.doi.org/ 10.5772/intechopen.81888
References
[1] Puchtler H, Sweat F. A review 
of early concepts of amyloid in 
context with contemporary chemical 
literature from 1839 to 1859. The 
Journal of Histochemistry and 
Cytochemistry. 1966;2:123-134. DOI: 
doi.org/10.1177/14.2.123
[2] Chiti F, Dobson CM. Protein 
misfolding, amyloid formation, 
and human disease: A summary 
of progress over the last decade. 
Annual Review of Biochemistry. 
2017;20(86):27-68. DOI: 10.1146/
annurev-biochem-061516-045115
[3] Kayed R, Head E, Thompson JL, 
Mcintire TM, Milton SC, Cotman CW, 
et al. Common structure of soluble 
amyloid oligomers implies common 
mechanism of pathogenesis. Science. 
2003;5618:486-489. DOI: 10.1126/
science.1079469
[4] Knowles TP, Fitzpatrick AW, Meehan 
S, Mott HR, Vendruscolo M, Dobson 
CM, et al. Role of intermolecular 
forces in defining material properties 
of protein nanofibrils. Science. 
2007;318(5858):1900-1903. DOI: 
10.1126/science.1150057
[5] Tipping KW, van Oosten-Hawle P, 
Hewitt EW, Radford SE. Amyloid fibres: 
Inert end-stage aggregates or key players 
in disease? Trends in Biochemical 
Sciences. 2015;(12):719-727. DOI: 
10.1016/j.tibs.2015.10.002
[6] Smaoui MR, Poitevin F, Delarue 
M, Koehl P, Orland H, Waldispühl 
J. Computational assembly of 
polymorphic amyloid fibrils reveals 
stable aggregates. Biophysical Journal. 
2013;(3):683-693. DOI: 10.1016/j.
bpj.2012.12.037
[7] Balchin D, Hayer-Hartl M, Hartl FU. In 
vivo aspects of protein folding and quality 
control. Science. 2016;353:aac4354. DOI: 
10.1126/science.aac4354
[8] Gustot A, Gallea JI, Sarroukh R, 
Celej MS, Ruysschaert JM, Raussens 
V. Amyloid fibrils are the molecular 
trigger of inflammation in Parkinson's 
disease. The Biochemical Journal. 
2015;(3):323-333. DOI: 10.1042/
BJ20150617
[9] Gustot A, Raussens V, Dehousse M, 
Dumoulin M, Bryant CE, Ruysschaert 
JM, et al. Activation of innate immunity 
by lysozyme fibrils is critically 
dependent on cross-β sheet structure. 
Cellular and Molecular Life Sciences. 
2013;(16):2999-3012. DOI: 10.1007/
s00018-012-1245-5
[10] Azevedo EP, Guimarães-Costa 
AB, Torezani GS, Braga CA, Palhano 
FL, Kelly JW, et al. Amyloid fibrils 
trigger the release of neutrophil 
extracellular traps (NETs), causing 
fibril fragmentation by NET-associated 
elastase. The Journal of Biological 
Chemistry. 2012;(44):37206-37218. 
DOI: 10.1074/jbc.M112.369942
[11] Benditt EP, Eriksen N. Chemical 
similarity among amyloid substances 
associated with long standing 
inflammation. Laboratory Investigation. 
1972;6:615-625
[12] Schumacher HR Jr. Multiple 
myeloma with synovial amyloid 
deposition. Rheumatology and Physical 
Medicine. 1972;7:349-353
[13] Sack GH Jr. Serum amyloid a - A 
review. Molecular Medicine. 2018;1:46. 
DOI: 10.1186/s10020-018-0047-0
[14] Itagaki S, McGeer PL, Akiyama 
H, Zhu S, Selkoe D. Relationship of 
microglia and astrocytes to amyloid 
deposits of Alzheimer disease. Journal 
of Neuroimmunology. 1989;(3):173-182
[15] Vostrikov VM. Electron-
cytochemical study of microglia in 
Alzheimer's disease and senile dementia. 
Amyloid Diseases
12
Zhurnal Nevropatologii i Psikhiatrii 
Imeni S.S. Korsakova. 1985;7:974-976
[16] Rozemuller JM, Eikelenboom P, 
Stam FC. Role of microglia 
in plaque formation in senile 
dementia of the Alzheimer type. An 
immunohistochemical study. Virchows 
Archiv. B, Cell Pathology Including 
Molecular Pathology. 1986;51:247-254
[17] Dos Santos Picanco LC, Ozela PF, 
de Fatima de Brito Brito M, Pinheiro 
AA, Padilha EC, Braga FS, et al. 
Alzheimer's disease: A review from 
the pathophysiology to diagnosis, 
new perspectives for pharmacological 
treatment. Current Medicinal 
Chemistry. 2018;(26):3141-3159. DOI: 
10.2174/0929867323666161213101126
[18] Barage SH, Sonawane KD. Amyloid 
cascade hypothesis: Pathogenesis and 
therapeutic strategies in Alzheimer's 
disease. Neuropeptides. 2015;52:1-18. 
DOI: 10.1016/j.npep.2015.06.008
[19] Karch CM, Cruchaga C, Goate 
AM. Alzheimer's disease genetics: 
From the bench to the clinic. Neuron. 
2014;(1):11-26. DOI: 10.1016/j.
neuron.2014.05.041
[20] Ill-Raga G, Ramos-Fernández E, 
Guix FX, Tajes M, Bosch-Morató M, 
Palomer E, et al. Amyloid-β peptide 
fibrils induce nitro-oxidative stress in 
neuronal cells. Journal of Alzheimer's 
Disease. 2010;2:641-652. DOI: 10.3233/
JAD-2010-100474
[21] Joshi P, Turola E, Ruiz A, Bergami 
A, Libera DD, Benussi L, et al. Microglia 
convert aggregated amyloid-β into 
neurotoxic forms through the shedding 
of microvesicles. Cell Death and 
Differentiation. 2014;(4):582-593. DOI: 
10.1038/cdd.2013.180
[22] Maphis N, Xu G, Kokiko-Cochran 
ON, Jiang S, Cardona A, Ransohoff 
RM, et al. Reactive microglia drive 
tau pathology and contribute to the 
spreading of pathological tau in the 
brain. Brain. 2015;6:1738-1755. DOI: 
10.1093/brain/awv081
[23] Ledo JH, Azevedo EP, Clarke JR, 
Ribeiro FC, Figueiredo CP, Foguel D, 
et al. Amyloid-β oligomers link 
depressive-like behavior and cognitive 
deficits in mice. Molecular Psychiatry. 
2013;10:1053-1054. DOI: 10.1038/
mp.2012.168
[24] Ginhoux F, Greter M, Leboeuf 
M, Nandi S, See P, Gokhan S, et al. 
Fate mapping analysis reveals 
that adult microglia derive from 
primitive macrophages. Science. 
2010;(6005):841-845. DOI: 10.1126/
science.1194637
[25] Prinz M, Mildner A. Microglia in the 
CNS: Immigrants from another world. 
Glia. 2011;(2):177-187. DOI: 10.1002/
glia.21104
[26] Tambuyzer BR, Ponsaerts P, 
Nouwen EJ. Microglia: Gatekeepers of 
central nervous system immunology. 
Journal of Leukocyte Biology. 
2009;(3):352-370. DOI: 10.1189/
jlb.0608385
[27] Jana M, Palencia CA, Pahan K. 
Fibrillar amyloid-beta peptides activate 
microglia via TLR2: Implications 
for Alzheimer's disease. Journal of 
Immunology. 2008;(10):7254-7262
[28] Fillit H, Ding WH, Buee L, Kalman 
J, Altstiel L, Lawlor B, et al. Elevated 
circulating tumor necrosis factor levels 
in Alzheimer's disease. Neuroscience 
Letters. 1991;(2):318-320
[29] Dickson DW. Neuropathological 
diagnosis of Alzheimer's disease: 
A perspective from longitudinal 
clinicopathological studies. 
Neurobiology of Aging. 1997;18:21-26
[30] Janelsins MC, Mastrangelo MA, 
Oddo S, LaFerla FM, Federoff HJ, 
Bowers WJ. Early correlation of 
13
The Role of Inflammation in Amyloid Diseases
DOI: http://dx.doi.org/ 10.5772/intechopen.81888
microglial activation with enhanced 
tumor necrosis factor-alpha and 
monocyte chemoattractant protein-1 
expression specifically within 
the entorhinal cortex of triple 
transgenic Alzheimer's disease mice. 
Journal of Neuroinflammation. 
2005;2:23
[31] Galimberti D, Fenoglio C, Scarpini 
E. Inflammation in neurodegenerative 
disorders: Friend or foe? Current Aging 
Science. 2008;1:30-41
[32] Montgomery SL, Bowers WJ. Tumor 
necrosis factor-alpha and the roles it 
plays in homeostatic and degenerative 
processes within the central nervous 
system. Journal of Neuroimmune 
Pharmacology. 2012;(1):42-59. DOI: 
10.1007/s11481-011-9287-2
[33] Kim DH, Choi SM, Jho J, Park 
MS, Kang J, Park SJ, et al. Infliximab 
ameliorates AD-associated object 
recognition memory impairment. 
Behavioural Brain Research. 
2016;311:384-391. DOI: 10.1016/j.
bbr.2016.06.001
[34] Lotz M, Ebert S, Esselmann H, 
Iliev AI, Prinz M, Wiazewicz N, et al. 
Amyloid beta peptide 1-40 enhances 
the action of toll-like receptor-2 and 
-4 agonists but antagonizes toll-like 
receptor-9-induced inflammation 
in primary mouse microglial cell 
cultures. Journal of Neurochemistry. 
2005;2:289-298
[35] Kayed R, Head E, Sarsoza F, Saing 
T, Cotman CW, Necula M, et al. Fibril 
specific, conformation dependent 
antibodies recognize a generic 
epitope common to amyloid fibrils 
and fibrillar oligomers that is absent 
in prefibrillar oligomers. Molecular 
Neurodegeneration. 2007;2:18
[36] Lee JJ, Wang PW, Yang IH, Wu CL, 
Chuang JH. Amyloid-beta mediates 
the receptor of advanced glycation end 
product-induced pro-inflammatory 
response via toll-like receptor 4 
signaling pathway in retinal ganglion 
cell line RGC-5. The International 
Journal of Biochemistry & Cell 
Biology. 2015;64:1-10. DOI: 10.1016/j.
biocel.2015.03.002
[37] Moore KJ, El Khoury J, Medeiros 
LA, Terada K, Geula C, Luster AD, 
et al. A CD36-initiated signaling 
cascade mediates inflammatory 
effects of beta-amyloid. The 
Journal of Biological Chemistry. 
2002;(49):47373-47379
[38] Salahuddin P, Rabbani G, 
Khan RH. The role of advanced 
glycation end products in various 
types of neurodegenerative disease: 
A therapeutic approach. Cellular 
& Molecular Biology Letters. 
2014;(3):407-437. DOI: 10.2478/
s11658-014-0205-5
[39] Gasparotto J, Ribeiro CT, da 
Rosa-Silva HT, Bortolin RC, Rabelo 
TK, Peixoto DO, et al. Systemic 
inflammation changes the site of RAGE 
expression from endothelial cells 
to neurons in different brain areas. 
Molecular Neurobiology. 2018. DOI: 
10.1007/s12035-018-1291-6
[40] Jarosz-Griffiths HH, Noble E, 
Rushworth JV, Hooper NM. Amyloid-β 
receptors: The good, the bad, and the 
prion protein. The Journal of Biological 
Chemistry. 2016;(7):3174-3183. DOI: 
10.1074/jbc.R115.702704
[41] Hansen DV, Hanson JE, Sheng M. 
Microglia in Alzheimer's disease. The 
Journal of Cell Biology. 2018;(2): 
459-472. DOI: 10.1083/jcb.201709069
[42] Harold D, Abraham R, 
Hollingworth P, Sims R, Gerrish A, 
Hamshere ML, et al. Genome-wide 
association study identifies variants 
at CLU and PICALM associated with 
Alzheimer's disease. Nature Genetics. 
2009;(10):1088-1093. DOI: 10.1038/
ng.440
Amyloid Diseases
14
[43] Zenaro E, Pietronigro E, Della 
Bianca V, Piacentino G, Marongiu L, 
Budui S, et al. Neutrophils promote 
Alzheimer's disease-like pathology and 
cognitive decline via LFA-1 integrin. 
Nature Medicine. 2015;(8):880-886. 
DOI: 10.1038/nm.3913
[44] Guimarães-Costa AB, Rochael NC, 
Oliveira F, Echevarria-Lima J, Saraiva 
EM. Neutrophil extracellular traps 
reprogram IL-4/GM-CSF-induced 
monocyte differentiation to anti-
inflammatory macrophages. Frontiers in 
Immunology. 2017;8:523. DOI: 10.3389/
fimmu.2017.00523
[45] O'Banion MK. Does peripheral 
inflammation contribute to Alzheimer 
disease? Evidence from animal models. 
Neurology. 2014;83:480-481. DOI: 
10.1212/WNL.0000000000000663
[46] Liliang PC, Liang CL, Lu K, Yang 
SN, Hsieh MT, Tai YC, et al. Population-
based study suggests an increased 
risk of Alzheimer'sdisease in Sjögren's 
syndrome. Clinical Rheumatology. 
2018;37:935-941. DOI: 10.1007/
s10067-017-3940-y
[47] Judge A, Garriga C, Arden 
NK, Lovestone S, Prieto-Alhambra 
D, Cooper C, et al. Protective 
effect of antirheumatic drugs on 
dementia in rheumatoid arthritis 
patients. Alzheimers Dement (N Y). 
2017;(4):612-621. DOI: 10.1016/j.
trci.2017.10.002
[48] Luchsinger JA, Cheng D, Tang 
MX, Schupf N, Mayeux R. Central 
obesity in the elderly is related to late-
onset Alzheimer disease. Alzheimer 
Disease and Associated Disorders. 
2012;(2):101-105. DOI: 10.1097/
WAD.0b013e318222f0d4
[49] Gustafson D, Rothenberg E, 
Blennow K, Steen B, Skoog I. An 18-year 
follow-up of overweight and risk of 
Alzheimer disease. Archives of Internal 
Medicine. 2003;(13):1524-1528
[50] Sterner RM, Takahashi PY, 
Yu Ballard AC. Active vaccines for 
alzheimer disease treatment. Journal 
of the American Medical Directors 
Association. 2016;(9):862.e11-862.e15. 
DOI: 10.1016/j.jamda.2016.06.009
[51] Zhang HY, Zhu K, Meng Y, Ding L, 
Wang JC, Yin WC, et al. Reduction of 
amyloid beta by Aβ3-10-KLH vaccine 
also decreases tau pathology in 3×Tg-
AD mice. Brain Research Bulletin. 
2018;142:233-240. DOI: 10.1016/j.
brainresbull.2018.07.019
[52] Panza F, Frisardi V, Solfrizzi V, 
Imbimbo BP, Logroscino G, Santamato 
A, et al. Immunotherapy for Alzheimer's 
disease: From anti-β-amyloid to 
tau-based immunization strategies. 
Immunotherapy. 2012;2:213-238. DOI: 
10.2217/imt.11.170
[53] Rua R, McGavern DB. Advances 
in meningeal immunity. Trends in 
Molecular Medicine. 2018;(6):542-559. 
DOI: 10.1016/j.molmed.2018.04.003
[54] Monsonego A, Zota V, Karni A, 
Krieger JI, Bar-Or A, Bitan G, et al. 
Increased T cell reactivity to amyloid 
beta protein in older humans and 
patients with Alzheimer disease. The 
Journal of Clinical Investigation. 
2003;(3):415-422
[55] Vieira M, Saraiva MJ. Transthyretin: 
A multifaceted protein. Biomolecular 
Concepts. 2014;1:45-54. DOI: 10.1515/
bmc-2013-0038
[56] Almeida MR, Alves IL, Terazaki 
H, Ando Y, Saraiva MJ. Comparative 
studies of two transthyretin variants 
with protective effects on familial 
amyloidotic polyneuropathy: TTR 
R104H and TTR T119M. Biochemical 
and Biophysical Research 
Communications. 2000;270:1024-1028
[57] Soares ML, Coelho T, Sousa A, 
Batalov S, Conceição I, Sales-Luís ML, 
et al. Susceptibility and modifier genes 
15
The Role of Inflammation in Amyloid Diseases
DOI: http://dx.doi.org/ 10.5772/intechopen.81888
in Portuguese transthyretin V30M 
amyloid polyneuropathy: Complexity in 
a single-gene disease. Human Molecular 
Genetics. 2005;(4):543-553
[58] Hurshman Babbes AR, Powers ET, 
Kelly JW. Quantification of the 
thermodynamically linked quaternary 
and tertiary structural stabilities of 
transthyretin and its disease-associated 
variants: The relationship between 
stability and amyloidosis. Biochemistry. 
2008;47:6969-6984. DOI: 10.1021/
bi800636q
[59] Planté-Bordeneuve V, Said G. 
Familial amyloid polyneuropathy. 
Lancet Neurology. 2011;10:1086-1097
[60] Benson MD. Liver transplantation 
and transthyretin amyloidosis. Muscle 
& Nerve. 2013;47:157-162
[61] Coelho T, Maia LF, da Silva AM, 
Cruz MW, Planté-Bordeneuve V, 
Suhr OB, et al. Long-term effects 
of tafamidis for the treatment of 
transthyretin familial amyloid 
polyneuropathy. Journal of Neurology. 
2013;260:2802-2814
[62] Benson MD, Waddington-Cruz 
M, Berk JL, Polydefkis M, Dyck PJ, 
Wang AK, et al. Inotersen treatment for 
patients with hereditary transthyretin 
amyloidosis. The New England Journal 
of Medicine. 2018;379:22-31. DOI: 
10.1056/NEJMoa1716793
[63] Sousa MM, Du Yan S, Fernandes 
R, Guimaraes A, Stern D, Saraiva 
MJ. Familial amyloid polyneuropathy: 
Receptor for advanced glycation end 
products-dependent triggering of 
neuronal inflammatory and apoptotic 
pathways. The Journal of Neuroscience. 
2001;21:7576-7586
[64] Gonçalves NP, Vieira P, 
Saraiva MJ. Interleukin-1 signaling 
pathway as a therapeutic target in 
transthyretin amyloidosis. Amyloid. 
2014;21:175-184
[65] Coutinho P, Martins da Silva A, 
Lopes Lima J, Resende Barbosa A. In: 
Glenner GG, Pinho e Costa P, Falcao 
de Freitas A, editors. Amyloid and 
Amyloidosis. Amsterdam: Excerpta 
Medica; 1980. Forty years of experience 
with type I amyloid neuropathy. Review 
of 483 cases. pp. 88-98
[66] Sousa MM, do Amaral JB, 
Guimarães A, Saraiva MJ. Up-regulation 
of the extracellular matrix remodeling 
genes, biglycan, neutrophil gelatinase-
associated lipocalin, and matrix 
metalloproteinase-9 in familial amyloid 
polyneuropathy. The FASEB Journal. 
2005;19:124-126
[67] Stone PJ, Campistol JM, Abraham 
CR, Rodgers O, Shirahama T, Skinner 
M. Neutrophil proteases associated 
with amyloid fibrils. Biochemical and 
Biophysical Research Communications. 
1993;197:130-136
[68] Buxbaum JN, Tagoe C, Gallo G, 
Walker JR, Kurian S, Salomon DR. 
Why are some amyloidoses systemic? 
Does hepatic "chaperoning at a 
distance" prevent cardiac deposition 
in a transgenic model of human senile 
systemic (transthyretin) amyloidosis? 
The FASEB Journal. 2012;26:2283-2293
[69] Kurian SM, Novais M, Whisenant T, 
Gelbart T, Buxbaum JN, Kelly JW, et al. 
Peripheral blood cell gene expression 
diagnostic for identifying symptomatic 
transthyretin amyloidosis patients: 
Male and female specific signatures. 
Theranostics. 2016;6:1792-1809
[70] Suenaga G, Ikeda T, Masuda T, 
Motokawa H, Yamashita T, Takamatsu 
K, et al. Inflammatory state exists 
in familial amyloid polyneuropathy 
that may be triggered by mutated 
transthyretin. Scientific Reports. 
2017;7:1579
[71] Scheller J, Chalaris A, Schmidt-
Arras D, Rose-John S. The pro- and anti-
inflammatory properties of the cytokine 
Amyloid Diseases
16
interleukin-6. Biochimica et Biophysica 
Acta. 2011;1813:878-888
[72] Urano F, Wang X, Bertolotti A, 
Zhang Y, Chung P, Harding HP, 
et al. Coupling of stress in the ER to 
activation of JNK protein kinases by 
transmembrane protein kinase IRE1. 
Science. 2000;287:664-666
[73] Liaskou E, Wilson DV, Oo 
YH. Innate immune cells in liver 
inflammation. Mediators of 
Inflammation. 2012;2012:949157
[74] Helk E, Bernin H, Ernst T, Ittrich H, 
Jacobs T, Heeren J, et al. TNFα-mediated 
liver destruction by kupffer cells and 
Ly6Chi monocytes during entamoeba 
histolytica infection. PLoS Pathogens. 
2013;9:e1003096
[75] Lladó L, Baliellas C, Casasnovas 
C, Ferrer I, Fabregat J, Ramos E, et al. 
Risk of transmission of systemic 
transthyretin amyloidosis after 
domino liver transplantation. Liver 
Transplantation. 2010;16:1386-1392
[76] Schonhoft JD, Monteiro C, Plate 
L, Eisele YS, Kelly JM, Boland D, 
et al. Peptide probes detect misfolded 
transthyretin oligomers in plasma of 
hereditary amyloidosis patients. Science 
Translational Medicine. 2017;9(407). 
DOI: 10.1126/scitranslmed.aam7621
[77] Reixach N, Deechongkit S, Jiang X, 
Kelly JW, Buxbaum JN. Tissue damage 
in the amyloidoses: Transthyretin 
monomers and nonnative oligomers 
are the major cytotoxic species in tissue 
culture. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2004;101:2817-2822
[78] Assenza S, Adamcik J, Mezzenga R, 
De Los Rios P. Universal behavior in the 
mesoscale properties of amyloid fibrils. 
Physical Review Letters. 2014;113:268103
[79] Maji SK, Perrin MH, Sawaya MR, 
Jessberger S, Vadodaria K, Rissman 
RA, et al. Functional amyloids as 
natural storage of peptide hormones in 
pituitary secretory granules. Science. 
2009;5938:328-332
[80] Fowler DM, Koulov AV, Balch WE, 
Kelly JW. Functional amyloid -from 
bacteria to humans. Trends in Biochemical 
Sciences. 2007;32:217-224
[81] Brochard V, Combadière B, 
Prigent A, Laouar Y, Perrin A, Beray-
Berthat V, et al. Infiltration of CD4+ 
lymphocytes into the brain contributes 
to neurodegeneration in a mouse model 
of Parkinson disease. The Journal of 
Clinical Investigation. 2009;119: 
182-192. DOI: 10.1172/JCI36470
[82] McGeer PL, Itagaki S, Boyes BE, 
McGeer EG. Reactive microglia 
are positive for HLA-DR in the 
substantia nigra of Parkinson's and 
Alzheimer's disease brains. Neurology. 
1988;38:1285-1291
[83] Blum-Degen D, Müller T, Kuhn 
W, Gerlach M, Przuntek H, Riederer 
P. Interleukin-1 beta and interleukin-6 
are elevated in the cerebrospinal fluid 
of Alzheimer's and de novo Parkinson's 
disease patients. Neuroscience Letters. 
1995;202:17-20
[84] Reale M, Iarlori C, Thomas A, 
Gambi D, Perfetti B, Di Nicola M, 
et al. Peripheral cytokines profile in 
Parkinson's disease. Brain, Behavior, 
and Immunity. 2009;23:55-63. DOI: 
10.1016/j.bbi.2008.07.003
[85] Joshi N, Singh S. Updates on 
immunity and inflammation in 
Parkinson disease pathology. Journal of 
Neuroscience Research. 2018;96: 
379-390. DOI: 10.1002/jnr.24185
[86] Caputi V, Giron MC. Microbiome-
gut-brain axis and toll-like 
receptors in Parkinson's disease. 
International Journal of Molecular 
Sciences. 2018;19(6). DOI: 10.3390/
ijms19061689
17
The Role of Inflammation in Amyloid Diseases
DOI: http://dx.doi.org/ 10.5772/intechopen.81888
[87] Geschwind MD. Prion diseases. 
Continuum (Minneap Minn). 
2015;6:1612-1638. DOI: 10.1212/
CON.0000000000000251
[88] Brown DR, Kretzschmar 
HA. Microglia and prion disease: A 
review. Histology and Histopathology. 
1997;12:883-892
[89] Douet JY, Lacroux C, Litaise C, 
Lugan S, Corbière F, Arnold M, et al. 
Mononucleated blood cell populations 
display different abilities to transmit 
prion disease by the transfusion route. 
Journal of Virology. 2016;90:3439-3445. 
DOI: 10.1128/JVI.02783-15
[90] Hung SY, Fu WM. Drug candidates 
in clinical trials for Alzheimer's 
disease. Journal of Biomedical 
Science. 2017;24:47. DOI: 10.1186/
s12929-017-0355-7
[91] Muthuraman M, Koirala N, Ciolac 
D, Pintea B, Glaser M, Groppa S, et al. 
Deep brain stimulation and L-DOPA 
therapy: Concepts of action and clinical 
applications in Parkinson's disease. 
Frontiers in Neurology. 2018;9:711. DOI: 
10.3389/fneur.2018.00711
[92] Bulawa CE, Connelly S, Devit M, 
Wang L, Weigel C, Fleming JA, et al. 
Tafamidis, a potent and selective 
transthyretin kinetic stabilizer 
that inhibits the amyloid cascade. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2012;109:9629-9634. DOI: 
10.1073/pnas.1121005109
[93] Adams D, Cauquil C, Labeyrie C, 
Beaudonnet G, Algalarrondo V, 
Théaudin M. TTR kinetic stabilizers 
and TTR gene silencing: A new era 
in therapy for familial amyloidotic 
polyneuropathies. Expert Opinion on 
Pharmacotherapy. 2016;(6):791-802. 
DOI: 10.1517/14656566.2016.1145664
[94] Murphy EJ. Acute pain management 
pharmacology for the patient with 
concurrent renal or hepatic disease. 
Anaesthesia and Intensive Care. 
2005;33:311-322
[95] Miguel-Álvarez M, Santos-Lozano 
A, Sanchis-Gomar F, Fiuza-Luces 
C, Pareja-Galeano H, Garatachea N, 
et al. Non-steroidal anti-inflammatory 
drugs as a treatment for Alzheimer's 
disease: A systematic review and meta-
analysis of treatment effect. Drugs & 
Aging. 2015;32:139-147. DOI: 10.1007/
s40266-015-0239-z
[96] Samii A, Etminan M, Wiens 
MO, Jafari S. NSAID use and 
the risk of Parkinson's disease: 
Systematic review and meta-analysis 
of observational studies. Drugs 
& Aging. 2009;26:769-779. DOI: 
10.2165/11316780-000000000-00000
